Education
About Us
Working with TipRanks
Follow Us
Akebia Therapeutics (AKBA)
NASDAQ:AKBA
AKBA Stock Chart & Stats
$1.66
$0.30(14.49%)
At close: 4:00 PM EST
$1.66
$0.30(14.49%)
Day’s Range― - ―
52-Week Range$1.45 - $4.08
Previous CloseN/A
Volume5.66M
Average Volume (3M)3.06M
Market Cap
$440.51M
Enterprise Value$794.19M
Total Cash (Recent Filing)$166.44M
Total Debt (Recent Filing)$52.58M
Price to Earnings (P/E)―
Beta1.16
Next Earnings
Mar 12, 2026EPS Estimate
<0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding265,366,000
10 Day Avg. Volume2,499,068
30 Day Avg. Volume3,061,474
Financial Highlights & Ratios
PEG Ratio-0.32
Price to Book (P/B)-8.15
Price to Sales (P/S)2.50
P/FCF Ratio-9.85
Enterprise Value/Market Cap1.80
Enterprise Value/Revenue3.53
Enterprise Value/Gross Profit4.48
Enterprise Value/Ebitda37.41
Forecast
1Y Price Target
$5.67Price Target Upside241.57% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)0.03
Revenue Forecast (FY)$239.31M
Bulls Say, Bears Say
Bulls Say
AcquisitionsThe acquisition of AKB-097 and the initiation of Phase 2 trials for Praliciguat are seen as positive developments, offering diversification and upside beyond current products.
Clinical TrialsA Phase 2 clinical trial in FSGS has recently been initiated, targeting a market with no approved therapies specifically indicated for the disease.
Market ExpansionThe company's focus on expanding dialysis center access and patient utilization for VAFSEO represents significant growth potential in the CKD dialysis market.
Bears Say
Clinical Trials DisappointmentThe decision not to pursue the Phase 3 VALOR trial for the CKD non-dialysis market was disappointing based on the commercial opportunity in CKD non-dialysis patients.
Market Opportunity LossThe removal of the CKD non-dialysis opportunity reflects the loss of a multi-billion-dollar market with approximately 550K anemia patients that are not on dialysis.
Patient Adherence ChallengesOne interesting point was the discussion of patient adherence on VAFSEO, specifically at the stage of the first refill on therapy immediately following the initial prescription.
Akebia Therapeutics News
AKBA FAQ
What was Akebia Therapeutics’s price range in the past 12 months?
Akebia Therapeutics lowest stock price was $1.45 and its highest was $4.08 in the past 12 months.
What is Akebia Therapeutics’s market cap?
Akebia Therapeutics’s market cap is $440.51M.
When is Akebia Therapeutics’s upcoming earnings report date?
Akebia Therapeutics’s upcoming earnings report date is Mar 12, 2026 which is in 72 days.
How were Akebia Therapeutics’s earnings last quarter?
Akebia Therapeutics released its earnings results on Nov 10, 2025. The company reported $0 earnings per share for the quarter, beating the consensus estimate of -$0.011 by $0.011.
Is Akebia Therapeutics overvalued?
According to Wall Street analysts Akebia Therapeutics’s price is currently Undervalued.
Does Akebia Therapeutics pay dividends?
Akebia Therapeutics does not currently pay dividends.
What is Akebia Therapeutics’s EPS estimate?
Akebia Therapeutics’s EPS estimate is <0.01.
How many shares outstanding does Akebia Therapeutics have?
Akebia Therapeutics has 265,366,000 shares outstanding.
What happened to Akebia Therapeutics’s price movement after its last earnings report?
Akebia Therapeutics reported an EPS of $0 in its last earnings report, beating expectations of -$0.011. Following the earnings report the stock price went down -18.137%.
Which hedge fund is a major shareholder of Akebia Therapeutics?
Currently, no hedge funds are holding shares in AKBA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Akebia Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$5.67 (241.57% Upside)
$5.67 (241.57% Upside)
Blogger Sentiment
Neutral
AKBA Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 806.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 5.6%
Last 30 Days ▲ 5.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-13.98%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
75.80%
Trailing 12-Months
Company Description
Akebia Therapeutics
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
AKBA Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflects a mix of strong prescription growth and financial improvements, offset by operational and adherence challenges impacting Vafseo's rollout. While revenue and patient access have grown significantly, the company faces hurdles in addressing logistics and adherence issues to sustain this growth.View all AKBA earnings summariesAKBA Stock 12 Month Forecast
Average Price Target
$5.67
▲(241.57% Upside)
Technical Analysis
Oruka Therapeutics
―
Theravance Biopharma
―
Vir Biotechnology
―
ProKidney
―
ArriVent BioPharma, Inc.
―
Ownership Overview
2.26% Insiders
9.50% Mutual Funds
4.81% Other Institutional Investors
69.10% Public Companies and Individual Investors